Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

摘要: Purpose To evaluate the outcome of intravitreal injection aflibercept in cases with exudative age-related macular degeneration, (AMD) resistant to injections bevacizumab or ranibizumab. Design Retrospective observational case series. Methods A retrospective chart review at a single institution was conducted identify patients AMD and choroidal neovascularization (CNV) 1 both eyes treatment ranibizumab who were switched least 3 monthly aflibercept. In total, 36 from 31 included. The demographic data, visual acuities, central thickness on optical coherence tomography (OCT), complications, number reviewed. Results mean patient age 79 years (range 60-88). There 13 male 18 female patients. prior either ranged 6-74. After aflibercept, there reduction subretinal intraretinal fluid (50.0%) treated eyes; amount remained stable 15 (41.7%) worsened 3 (8.3%). significant average decrease observed for after 65 μm ( P  = 2.9 × 10 -6 ), no change acuity. Conclusions Aflibercept therapy appears be beneficial subset neovascular degeneration exhibit recurrent following multiple